Skip Navigation



NDT Advance Access published online on March 29, 2007
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfm136
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/7/1853    most recent
gfm136v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Decaux, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Decaux, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

V2-antagonists for the treatment of hyponatraemia*

Guy Decaux

Department of General Internal Medicine, Erasme University Hospital, Brussels, Belgium

Correspondence and offprint requests to: Guy Decaux, Department of General Internal Medicine, Erasme University Hospital, Brussels, Belgium. Email: guy.decaux@skynet.be

Keywords: hyponatraemia; vasopressin; V2-receptor antagonist

The first 10% of the full text of this article appears below.

Hypotonic hyponatraemia results from an excess of total body water relative to the exchangeable sodium and potassium pool due to a decrease in electrolyte-free water (EFWC) excretion [1]. The decrease in free water excretion is mostly due to the secretion of the antidiuretic hormone (ADH), also called vasopressin. This secretion is either ‘appropriate’ when it is a result of volume stimuli, or ‘inappropriate’, as in the syndrome of inappropriate secretion of ADH (SIADH), when osmotic or volume stimuli are lacking. Vasopressin is involved in most cases of sustained hyponatraemia. Therefore, the use of specific blockers of vasopressin receptors is a logical approach in the treatment of patients with SIADH or hypervolemic hyponatraemia and may offer . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?